Fundz

Intensity Therapeutics

Shelton, United States · Biotechnology, Health Care, Manufacturing · 9 employees

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated i

Funding history

  • Funding Round — $4.0M — Oct 2025
  • Series seed — $3.6M — Dec 2024
  • Series seed — $500K — Jun 2015

Recent signals

  • Mar 27, 2026: SEC 8-K (2.02): On March 27, 2026, Intensity Therapeutics, Inc. released its financial results for the year ended December 31, 2025. The press release, attached as Exhibit 99.1, outlines the Company's performance metrics, financial condition, and operational changes throughout the fiscal year. The significant context of this release is to inform shareholders about the company's financial health, which can influence stock performance and investment decisions. This report is particularly relevant for stakeholders looking for insights into the company's profitability and growth prospects based on the latest annual results.
  • Mar 05, 2026: SEC 8-K (8.01): On March 5, 2026, Intensity Therapeutics, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of the company's common stock of $1.00 per share. This compliance was achieved by maintaining the required price for the previous 10 consecutive business days, from February 19, 2026, through March 4, 2026. Following a previous compliance notice from Nasdaq on June 6, 2025, indicating non-compliance, this development is significant for the company as it removes the threat of delisting from the Nasdaq Stock Market. The matter is now closed, allowing the company to continue listing its shares without restrictions.
  • Oct 31, 2025: Raised $4.0M
  • Oct 30, 2025: SEC 8-K (1.01): On October 30, 2025, Intensity Therapeutics, Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell 5,000,000 shares of common stock at a price of $0.80 per share. This transaction is expected to generate aggregate gross proceeds of $4.0 million for the company before deducting placement agent fees and related expenses. The offering is being conducted under a Registration Statement on Form S-3 previously filed with the SEC. This capital raise is aimed at financing the company's strategic initiatives and enhancing its operational capabilities.
  • Oct 22, 2025: SEC 8-K (5.07): On October 22, 2025, Intensity Therapeutics, Inc. held a special meeting of stockholders where significant matters were submitted for a vote. The meeting witnessed the representation of 22,869,562 shares, approximately 46.61% of outstanding shares, indicating a quorum. One of the key proposals voted on was for a reverse stock split as part of an amendment to the company's Amended and Restated Certificate of Incorporation, the details of which were outlined in a prior proxy statement filed on September 9, 2025. This move could significantly impact the company's share structure and stock price, enhancing its listing appeal on the Nasdaq Stock Market, where it trades under the symbol INTS.
  • Dec 05, 2024: Raised $3.6M in Series seed
  • Dec 12, 2023: Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
  • Jun 12, 2015: Raised $500K in Series seed

See plans & pricing → Track Intensity Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.